Replication-selective oncolytic adenoviruses: virotherapy aimed at genetic targets in cancer (original) (raw)
References
Agha-Mohammadi S and Lotze M. . 2000 J. Clin. Invest.105: 1173–1176.
Asada T. . 1974 Cancer34: 1907–1928.
Barker DD and Berk AJ. . 1987 Virology156: 107–121.
Bischoff JR, Kirn DH, Williams A, Heise C, Horn S, Muna M, Ng L, Nye JA, Sampson-Johannes A, Fattaey A and McCormick F. . 1996 Science274: 373–376.
Chinnadurai G. . 1983 Cell33: 759–766.
Coffey M, Strong J, Forsyth P and Lee P. . 1998 Science282: 1332–1334.
Dimitrov T, Krajcsi P, Hermiston TW, Tollefson AE, Hannink M and Wold WS. . 1997 J. Virol.71: 2830–2837.
Dobner T, Horikoshi N, Rubenwolf S and Shenk T. . 1996 Science272: 1470–1473.
Doronin K, Toth K, Kuppuswamy M, Ward P, Tollefson A and Wold W. . 2000 J. Virol.74: 6147–6155.
Douglas JT, Rogers BE, Rosenfeld ME, Michael SI, Feng M and Curiel DT. . 1996 Nat. Biotechnol.14: 1574–1578.
Freytag SO, Rogulski KR, Paielli DL, Gilbert JD and Kim JH. . 1998 Hum. Gene. Ther.9: 1323–1333.
Fueyo J, Gomez-Manzano C, Alemany R, Lee P, McDonnell T, Mitlianga P, Shi Y, Levin V, Yung W and Kyritsis A. . 2000 Oncogene19: 2–12.
Ganly I, Kirn D, Eckhardt S, Rodriguez G, Souter D, Von Hoff D and Kaye S. . 2000 Clin. Cancer Res.6: 798–806.
Gooding LR. . 1994 Infect. Agents Dis.3: 106–115.
Goodrum FD and Ornelles DA. . 1997 J. Virol.71: 548–561.
Goodrum FD and Ornelles DA. . 1998 J. Virol.72: 9479–9490.
Hallenbeck P. . 1999 Hum. Gene Ther.10: 1721–1733.
Harada J and Berk A. . 1999 J. Virol.73: 5333–5344.
Hawkins L, Nye J, Castro D, Johnson L, Kirn D and Hermiston T. . 1999 Proc. Am. Assoc. Cancer Res.40: 476.
Hecht R, Abbruzzesse J, Bedford R, Randlev B, Romel L, Lahodi S and Kirn D. . 2000 Proc. Am. Soc. Clin. Oncol.19: 1039 (abstract).
Heise C, Hermiston T, Johnson L, Brooks G, Sampson-Johannes A, Williams A, Hawkins L and Kirn D. . 2000a Nat. Med.6: 1134–1139.
Heise C and Kirn D. . 2000 J. Clin. Invest.105: 847–851.
Heise C, Lemmon M and Kirn D. . 2000b Clin. Cancer Res. (In press).
Heise C, Sampson-Johannes A, Williams A, McCormick F, Von Hoff DD and Kirn DH. . 1997 Nat. Med.3: 639–645.
Heise C, Williams A, Olesch J and Kirn D. . 1999a Cancer Gene Therapy6: 000–000.
Heise C, Williams A, Xue S, Propst M and Kirn D. . 1999b Cancer Res.59: 2623–2628.
Hermiston T. . 2000 J. Clin. Invest.105: 1169–1172.
Hermiston TW, Tripp RA, Sparer T, Gooding LR and Wold WS. . 1993 J. Virol.67: 5289–5298.
Hollstein M, Sidransky D, Vogelstein B and Harris CC. . 1991 Science253: 49–53.
Hu QJ, Dyson N and Harlow E. . 1990 EMBO J.9: 1147–1155.
Khuri F, Nemunaitis J, Ganly I, Gore M, MacDougal M, Tannock I, Kaye S, Hong W and Kirn D. . 2000 Nat. Med.6: 879–885.
Kirn D. . 2000a J. Clin. Invest.105: 836–838.
Kirn D. . 2000b Gene Therapy7: 815–816.
Kirn D, Heise C, Williams M, Propst M and Hermiston T. . 1998a Cancer Gene Therapy. Sobol (ed.): San Diego.
Kirn D, Hermiston T and McCormick F. . 1998b Nat. Med.4: 1341–1342.
Kurihara T, Brough DE, Kovesdi I and Kufe DW. . 2000 J. Clin. Invest.106: 763–771.
Lattime EC, Lee SS, Eisenlohr LC and Mastrangelo MJ. . 1996 Semin. Oncol.23: 88–100.
Low K, Ittensohn M, Le T, Platt J, Sodi S, Amoss M, Ash O, Carmichael E, Chakraborty A, Fischer J, Lin S, Luo X, Miller S, Zheng L, King I, Pawelek J and Bermudes D. . 1999 Nat. Biotech.17: 37–41.
Martuza R. . 2000 J. Clin. Invest.105: 841–846.
Martuza RL, Malick A, Markert JM, Ruffner KL and Coen DM. . 1991 Science252: 854–856.
Mastrangelo M, Eisenlohr L, Gomella L and Lattime E. . 2000 J. Clin. Invest.105: 1031–1034.
Medina DJ, Sheay W, Goodell L, Kidd P, White E, Rabson AB and Strair RK. . 1999 Blood94: 3499–3508.